Aim and Strategy

To improve treatment of gynecologic cancer, efforts have been made to perform comprehensive molecular profiling, both globally, like the TCGA initiative https://cancergenome.nih.gov/, but also by individual research groups. The Bergen Gynecologic Cancer research group has contributed with several important breakthroughs on molecular profiling of endometrial cancer in particular.

In parallel, several potent biomarkers have been identified, by us and others, which could better select patients for more individualized treatment. However, this knowledge has had little effect on current treatment practice.

The advances in molecular knowledge need to be followed by functional studies of both effect of specific molecular alterations (mutations, amplification/deletions or translational regulations) and potential link between a specific biomarker and response to drug treatment. Our research group focuses on expanding our knowledge on molecular alterations in gynecologic cancers and aims to perform functional studies to aid clinical implementation of relevant findings.